Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-08-22 / Blood 2017 10;130(15):1713-1721Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e5Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-08-01 / Melanoma Res 2017 08;27(4):351-357Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells : Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase
/in International Publications, Newcastle Disease Virus, Ovarian Cancer /von 2017-07-27 / J. Virol. 2017 08;91(16)Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report
/in Gallbladder Cancer, Hyperthermia, International Publications /von 2017-07-26 / Integr Cancer Ther 2018 06;17(2):558-561Recent developments in immunotherapy of acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-07-25 / J Hematol Oncol 2017 07;10(1):142Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
/in Brain Tumors in Children, International Publications /von 2017-07-25 / Front Pharmacol 2017;8:495Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-07-25 / J Glob Oncol 2018 Sep;4:1-4Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2017-07-19 / Int J Cancer 2017 11;141(9):1891-1900
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de